BOLT - Bolt Biotherapeutics, Inc. Stock Price, Fair Value and News

$5.20+0.21 (+4.21%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BOLT Price Action

Last 7 days

5.1%

Last 30 days

-6.8%

Last 90 days

7.4%

Trailing 12 Months

-58.4%

BOLT RSI Chart

BOLT Valuation

Market Cap

10.0M

Price/Earnings (Trailing)

-0.23

Price/Sales (Trailing)

1.92

Price/Free Cashflow

-0.19

BOLT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BOLT Fundamentals

BOLT Revenue

Revenue (TTM)

5.2M

Rev. Growth (Yr)

90.1%

Rev. Growth (Qtr)

20.23%

BOLT Earnings

Earnings (TTM)

-42.7M

Earnings Growth (Yr)

52.93%

Earnings Growth (Qtr)

16.55%

BOLT Profitability

Return on Equity

-132.96%

Return on Assets

-65.61%

Free Cashflow Yield

-525.05%

BOLT Investor Care

Shares Dilution (1Y)

0.30%

Diluted EPS (TTM)

-22.22

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	3.6M	4.2M	5.2M	0
2024	11.3M	11.2M	9.8M	7.7M
2023	6.7M	6.8M	7.2M	7.9M
2022	2.2M	3.5M	4.8M	5.7M
2021	0	269.0K	970.0K	1.4M
2020	0	0	0	257.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

CEO	Dr. Randall C. Schatzman Ph.D.
WEBSITE	boltbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	94

Bolt Biotherapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Bolt Biotherapeutics, Inc.? What does BOLT stand for in stocks?

BOLT is the stock ticker symbol of Bolt Biotherapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bolt Biotherapeutics, Inc. (BOLT)?

As of Wed Dec 03 2025, market cap of Bolt Biotherapeutics, Inc. is 9.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BOLT stock?

You can check BOLT's fair value in chart for subscribers.

Is Bolt Biotherapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether BOLT is over valued or under valued. Whether Bolt Biotherapeutics, Inc. is cheap or expensive depends on the assumptions which impact Bolt Biotherapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BOLT.

What is Bolt Biotherapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, BOLT's PE ratio (Price to Earnings) is -0.23 and Price to Sales (PS) ratio is 1.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BOLT PE ratio will change depending on the future growth rate expectations of investors.